A5086331567- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Neuropeptides and Animal Physiology
- Ophthalmology and Eye Disorders
- Cardiovascular Syncope and Autonomic Disorders
- Asthma and respiratory diseases
- Sympathectomy and Hyperhidrosis Treatments
- Glaucoma and retinal disorders
- Pain Mechanisms and Treatments
- Psychosomatic Disorders and Their Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pain Management and Opioid Use
- Pain Management and Treatment
University of Florence
2023-2025
A pharmacological class effect was initially proposed for monoclonal antibodies against the calcitonin gene related peptide pathway. However, preliminary evidence shows that switching patients who were non-responding to one antibody another could provide some benefit. Herein, we assess treatment response an anti-calcitonin peptide/receptor in have failed respond peptide/ligand and vice versa. In addition, select non-responders first anti- by three or five more stringent...
Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up. We aimed to evaluate the long-term (up 52 weeks) effectiveness tolerability of fremanezumab in high-frequency episodic chronic migraine. This s independent, prospective, multicenter cohort study enrolling outpatients 17 Italian Headache Centers or multiple preventive treatment failures. Patients were treated 225 mg monthly. The primary...
Background: Small molecule receptor antagonists (gepants), or monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) have recently become available for migraine prophylaxis and/or acute treatment. Considering their shared mechanisms of action, if the failure to an anti-CGRP(R) mAbs preclude effectiveness gepants vice versa is still unknown. Herein, we report first case a patient with refractory responsive use rimegepant that previously failed two different and no...
Background: Clinical studies have shown the efficacy and safety of monoclonal antibodies (mAbs) against calcitonin gene-related peptide (anti- CGRP) in migraine patients with without aura. Early evidence from post hoc small subgroup analyses suggests that anti-CGRP mAbs reduce frequency intensity Herein, we prospectively assessed changes aura after 12 months mAb treatment performed a literature review.Methods: All outpatients treated for one year two tertiary Headache Centers who experienced...
Emerging evidence suggests that primary headaches, classified as trigeminal autonomic cephalalgias (TACs), may exhibit sex and gender differences in clinical features, mechanisms, treatment responses. While epidemiological gender-specific have been widely reported for cluster headache, limited is available other TACs. In this narrative review, we analyzed the existing data on influence of paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, hemicrania continua....
Background The present study aimed to determine whether machine-learning (ML)-based models can predict 3-, 6, and 12-month responses the monoclonal antibodies (mAbs) against calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRPmAbs) in patients with migraine using early predictors (up one month) create an evolving prediction tool. Methods In this prospective cohort study, data from who had received anti-CGRP mAbs for 12 months were collected. Demographic monthly clinical...
The anti-calcitonin gene-related peptide (CGRP), or its receptor (CGRP/R) monoclonal antibodies (mAbs), offer targeted, effective, and tolerated drugs for migraine. However, about 25% of patients fail to achieve a clinically meaningful response, usually leading discontinuation. These often have lengthy migraine history multiple prior preventive treatment failures, resulting in limited therapeutic options. Herein, we describe the cause outcome withdrawal anti-CGRP/R mAb evaluate course until